The EXPOSURE study compared survival rates between pulmonary arterial hypertension (PAH) patients newly treated with selexipag versus other pulmonary arterial hypertension-specific therapies. Survival analyses in EXPOSURE suggest a reduced risk of mortality among the cohort of patients newly initiated on selexipag compared with the modelled cohort newly initiated with other pulmonary arterial hypertension-specific therapies. Further research
is needed to confrm this observation.
A plain language summary of this study is available, which we commend the authors for!
QUOTE
EXPOSURE is a post-approval study required by the European Medicines Agency, aimed at collecting data on patients with pulmonary arterial hypertension who are starting a new pulmonary arterial hypertension treatment in medical clinics. We analyzed 2014 patients, divided into two groups: one that started treatment with selexipag (selexipag group) and another that started other pulmonary arterial hypertension medication(s) (other pulmonary arterial hypertension therapy group). At the start of treatment, patients in the selexipag group had been diagnosed with pulmonary arterial hypertension for longer and showed less severe symptoms compared with the other pulmonary arterial hypertension therapy group. They were also more likely to be on a combination of at least two diferent pulmonary arterial hypertension medications at the time they started treatment with selexipag. Because of these diferences, we used statistical modelling to balance patient characteristics at the start of treatment to be able to compare the medications. After balancing the groups, our data suggest a lower relative risk of dying with selexipag treatment compared with treatment with other pulmonary arterial hypertension therapies.
UNQUOTE
Read more at this link on Springer Nature
Citation
Söderberg, S., Escribano-Subias, P., Archey, C. et al. Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study), Drugs – Real World Outcomes (2025). https://doi.org/10.1007/s40801-025-00488-9